| http://www.w3.org/ns/prov#value | - Healthcare providers should assess patients for cardiopulmonary disorders before and during treatment with dasatinib and permanently discontinue therapy in patients who develop PAH. Teach patients to immediately report signs and symptoms of PAH, such as dyspnea, fatigue, and fluid retention.Source: FDA drug safety communication: sprycel (dasatinib) and risk of pulmonary arterial hypertension. http
|
